Related references
Note: Only part of the references are listed.Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Diagnosis of fusion genes using targeted RNA sequencing
Erin E. Heyer et al.
NATURE COMMUNICATIONS (2019)
Next-generation characterization of the Cancer Cell Line Encyclopedia
Mahmoud Ghandi et al.
NATURE (2019)
fastp: an ultra-fast all-in-one FASTQ preprocessor
Shifu Chen et al.
BIOINFORMATICS (2018)
Development and Verification of an RNA Sequencing (RNA-Seq) Assay for the Detection of Gene Fusions in Tumors
Jennifer L. Winter et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
Sherise D. Ferguson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Theodore W. Laetsch et al.
LANCET ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
Qingsong Gao et al.
CELL REPORTS (2018)
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
S. -H. Lee et al.
ANNALS OF ONCOLOGY (2017)
High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods
Dan Su et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease
Alexandra Dumitriu et al.
BMC MEDICAL GENOMICS (2016)
The human transcriptome across tissues and individuals
Marta Mele et al.
SCIENCE (2015)
Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics
Linn Fagerberg et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel et al.
LANCET ONCOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Liang Shen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Current status and new features of the Consensus Coding Sequence database
Catherine M. Farrell et al.
NUCLEIC ACIDS RESEARCH (2014)
Tandem RNA Chimeras Contribute to Transcriptome Diversity in Human Population and Are Associated with Intronic Genetic Variants
Liliana Greger et al.
PLOS ONE (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
Alexander Drilon et al.
CANCER DISCOVERY (2013)
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Devendra Singh et al.
SCIENCE (2012)
RNA sequencing: advances, challenges and opportunities
Fatih Ozsolak et al.
NATURE REVIEWS GENETICS (2011)
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
Xuchao Zhang et al.
MOLECULAR CANCER (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Share Paper
